Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:AKLI

Akili (AKLI) Stock Price, News & Analysis

Akili logo

About Akili Stock (NASDAQ:AKLI)

Key Stats

Today's Range
$0.43
$0.43
50-Day Range
$0.42
$0.44
52-Week Range
$0.19
$1.25
Volume
N/A
Average Volume
2.20 million shs
Market Capitalization
$34.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.

Receive AKLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akili and its competitors with MarketBeat's FREE daily newsletter.

AKLI Stock News Headlines

Central Bank Abandons USD
You know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our exploding national debt, VOTE FOR GOLD!
See More Headlines

AKLI Stock Analysis - Frequently Asked Questions

Akili, Inc. (NASDAQ:AKLI) announced its quarterly earnings results on Thursday, May, 11th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.18) by $0.04. The company earned $0.11 million during the quarter. Akili had a negative net margin of 2,492.04% and a negative trailing twelve-month return on equity of 79.93%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Akili investors own include Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Tesla (TSLA), Taiwan Semiconductor Manufacturing (TSM), NVIDIA (NVDA), P3 Health Partners (PIII) and uniQure (QURE).

Company Calendar

Last Earnings
5/11/2023
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:AKLI
Fax
N/A
Employees
130
Year Founded
N/A

Profitability

Net Income
$-59,490,000.00
Net Margins
-2,492.04%
Pretax Margin
-2,489.32%

Debt

Sales & Book Value

Annual Sales
$1.95 million
Book Value
$0.75 per share

Miscellaneous

Free Float
70,776,000
Market Cap
$34.01 million
Optionable
Optionable
Beta
1.72
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NASDAQ:AKLI) was last updated on 11/22/2024 by MarketBeat.com Staff
From Our Partners